INOVIO to Participate in Upcoming Scientific Conferences

Rhea-AI Summary

INOVIO (NASDAQ:INO) will present at two scientific conferences in March 2026. Eurogin HPV Conference (Vienna) on March 19 at 8:00 AM CET: presentation on DNA immunotherapy INO-3107 and long-term surgical intervention reduction in HPV-6 and HPV-11 RRP. World Vaccine Congress DC (Washington, DC) on March 30 at 11:50 AM ET: presentation on DNA-encoded monoclonal antibody technology for durable, tolerable in vivo mAb expression targeting COVID. Available abstracts will be posted on INOVIO's website after presentations.

News Market Reaction – INO

-0.57%

-0.57% Session close to close

In the Mar 9 session, INO declined 0.57%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PLYMOUTH MEETING, Pa., March 9, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in the following scientific conferences:

Eurogin HPV Conference (Vienna, Austria)
Date: Thursday, March 19
Time: 8:00 AM CET
Presentation: DNA Immunotherapy INO-3107 Demonstrates Long-Term Surgical Intervention Reduction in HPV-6 & 11 RRP

World Vaccine Congress DC (Washington, DC)
Date: Monday, March 30
Time: 11:50 AM ET
Presentation: Novel DNA-Encoded Monoclonal Antibody Technology: Durable and Tolerable In Vivo Expression of mAbs Targeting COVID

Available abstracts will be shared on INOVIO's website following presentations.

About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Contacts
Media: Jennie Willson, (267) 429-8567, communications@inovio.com
Investors: Peter Vozzo, ICR Healthcare, (443) 213-0505, investor.relations@inovio.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-participate-in-upcoming-scientific-conferences-302707174.html

SOURCE INOVIO Pharmaceuticals, Inc.

FAQ

When will INOVIO (INO) present at the Eurogin HPV Conference and what is the topic?

INOVIO will present on March 19, 2026 at 8:00 AM CET about INO-3107 and surgical intervention reduction in HPV-6 and HPV-11 RRP. According to the company, the talk highlights long-term outcomes for their DNA immunotherapy.

What will INOVIO (INO) present at World Vaccine Congress DC and when is it scheduled?

INOVIO will present on March 30, 2026 at 11:50 AM ET on DNA-encoded monoclonal antibody technology targeting COVID. According to the company, the session covers durable, tolerable in vivo expression of monoclonal antibodies.

Will INOVIO (INO) share abstracts or materials from the March 2026 conference presentations?

Yes. According to the company, available abstracts will be posted on INOVIO's website following the presentations. This will provide slide summaries and study details after each conference session concludes.

How can investors or researchers attend INOVIO's (INO) March 2026 conference presentations?

Attend the in-person conference sessions on the scheduled dates or follow post-conference abstracts on INOVIO's website. According to the company, abstracts will be available online after the presentations for remote review.

What scientific programs will INOVIO (INO) emphasize in its March 2026 conference presentations?

INOVIO will emphasize DNA immunotherapy (INO-3107) for HPV-related RRP and DNA-encoded monoclonal antibody platforms for COVID. According to the company, both talks focus on clinical durability and tolerability data and long-term outcome measures.